Scientists hunt for ALS biomarkers in tiny muscle samples
NCT ID NCT02670226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find biological markers (biomarkers) in muscle, blood, and cells to help diagnose amyotrophic lateral sclerosis (ALS) earlier and understand the disease better. Researchers analyzed samples from 37 adults with ALS using advanced techniques to look at molecules and gene activity. The goal was to identify patterns that could lead to a diagnostic test, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
37 people
The number who actually took part.
- Started
-
Mar 2016
- Finished
-
Dec 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Case group selection criteria: Inclusion Criteria: * Age ≥ 18 years and ≥ 75 years * ALS according to the El Escorial criteria * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Pregnant or breastfeeding women * Contraindication to biopsy * Contraindication to local anesthesia * Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin) * Unbalanced Diabetes * Systemic corticosteroid treatment * Treatment against cramps or twitching may affect muscle metabolism Control group selection criteria: Inclusion Criteria: * Age ≥ 18 years and ≥ 75 years * No neuronal disease * Patients affiliated to social security scheme * Informed consent signed by the patient Exclusion Criteria: * Pregnant or breastfeeding women * Contraindication to biopsy * Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin) * Unbalanced Diabetes * Systemic corticosteroid treatment * Treatment against cramps or twitching may affect muscle metabolism
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Neurologie, CHRU de TOURS
Tours, 37044, France
-
Service de chirurgie orthopédique et traumatologique, CHRU de TOURS
Tours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing device tested to slow lung decline in ALS
- Can hospital codes reliably track home ventilation in ALS?
- Can a synthetic compound be safe enough to test in ALS? early trial asks
- Can a cheap gout drug slow ALS? trial puts colchicine to the test
- Can donor gut bacteria reshape the immune system in ALS?
- Spinal injection drug targets genetic cause of ALS and dementia